Mirati Therapeutics, Inc. (MRTX)
After hours:
| Previous close | 56.69 |
| Open | 56.56 |
| Bid | 56.38 x 1100 |
| Ask | 56.89 x 900 |
| Day's range | 56.31 - 56.76 |
| 52-week range | 27.30 - 64.41 |
| Volume | |
| Avg. volume | 2,307,987 |
| Market cap | 3.963B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.18 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 60.69 |
- Reuters
UPDATE 1-Mirati's lung cancer drug gets EU's regulatory backing
Mirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer. The European Medicine Agency's committee backed Krazati following a re-examination of the drug the panel had declined to back for authorization in July, saying the requirements for conditional support were not fulfilled, which Mirati had disagreed with. Krazati received the U.S. Food and Drug Administration's accelerated approval last year and also the UK health regulator's authorization earlier this month.
PR NewswireMirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy.
ZacksMirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.
